title: [Evaluation of the effect of nifedipine in patients with chronic congestive heart failure].
abstract: 18 patients with II NYHA class chronic congestive heart failure (CCHF) had been given nifedipine (Cordipin) 54.4 +/- 12.0 mg (day) for 6 weeks (group I). In 25 patients with III--IV NYHA class CCHF after 2-week optimal improvement of a clinical state with digoxine (D) and furosemide (F), nifedipine (N) had been added for 2 weeks/mean daily dose -- 40.8 +/- 12.8 mg (group II). Estimation of a left ventricular function using 2-DE and a submaximal effort tolerance as well as clinical examinations were carried out initially, after 2 and 6 weeks in group I, whereas in group II post D, F 2-week therapy and after next 2 weeks of combined D, F, N treatment. Nifedipine significantly increased ejection fraction from 44.2 +/- 13.0% to 49.0 +/- +/- 12.6% and decreased myocardial oxygen demand factor from 23.36 +/- 9.81 to 21.08 +/- 7.55 X 10(3) (p less than 0.05). Nonsignificant but marked increase of diuresis, cardiac and stroke indices as well as body weight loss were observed. Nifedipine addition to D and F neither improved nor deteriorated examined parameters in patients with III-IV NYHA class CCHF. Nifedipine did not also improve the submaximal exercise tolerance in both groups.
authors.forename: M
authors.initials: M
authors.lastname: Cholewa
authors.forename: L
authors.initials: L
authors.lastname: Górski
authors.forename: Z
authors.initials: Z
authors.lastname: Gawor
authors.forename: K
authors.initials: K
authors.lastname: Markiewicz
authors.forename: T
authors.initials: T
authors.lastname: Dryjański
authors.forename: J
authors.initials: J
authors.lastname: Bechler-Lisińska
authors.forename: B
authors.initials: B
authors.lastname: Broks-Bratkowska
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000008:administration & dosage; D004231:Diuresis / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005665:Furosemide / Q000008:administration & dosage; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D004077:Digoxin; D005665:Furosemide; D009543:Nifedipine
vernacular_title: Ocena działania nifedypiny u chorych na przewlekła zastoinowa niewydolność serca.